LONDON–(BUSINESS WIRE)–Jun 1, 2018–Market research firm has announced the release of their latest report on the global epilepsy drugs market. This new report will provide expert market insights for the forecast period 2018-2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180601005697/en/
Technavio has published a new market research report on the global epilepsy drugs market from 2018-2022. (Graphic: Business Wire)
The report will follow up on Technavio’s previous report on the global epilepsy drugs market, to offer an up-to-date analysis of the market with regards to the innovations, current competitive landscape and latest trends and drivers, to provide new predictions for the forecast period.
The upgraded research report on the is an integral part of Technavio’s central nervous system portfolio. Technavio covers an extensive range of market research reports on the central nervous system market, providing insights into the market growth opportunities. Some of the topics include pain management drugs, myelodysplastic syndrome, central nervous system (CNS) disorders therapeutics, and ankylosing spondylitis.
Global epilepsy drugs market: Market at a glance
Technavio’s previous report on the global epilepsy drugs market projected that in terms of geography, the Americas will continue to dominate the market through 2020. The growth of this market in the Americas is because of the high prevalence of the disorder and the availability of treatment options in the region, particularly in the developed markets such as the US and Canada. Approximately 1% of the population in Canada has epilepsy and approximately 15,000 new cases are diagnosed each year.
In the previous report, a senior research analyst at Technavio stated , “The tentative approval of several late-stage pipeline molecules is one of the key factors driving the growth of the epilepsy drug market. It has been observed that most of the drugs available in the market to treat epilepsy are only restricted to symptomatic treatment. Therefore, there is an augmented demand for the need for effective medications for epilepsy. This has led to a significant increase in investment in the R&D of new drugs by several companies.”
Technavio’s new report on the global epilepsy drugs market will evaluate the key geographical regions and their behavior over the past four years, introducing new data and observations and providing new predictions. This report is available to order now and will be delivered within one week of purchase.
Global epilepsy drugs market: Detailed analysis at your fingertips
Some of the topics that will be revisited in the new report include:
Market size forecast and growth rate through 2022Top factors driving the market growthCompetitive landscape and market share analysis of the key playersMarket growth opportunities and factors impeding growth
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180601005697/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 06/01/2018 12:41 PM/DISC: 06/01/2018 12:41 PM
Copyright Business Wire 2018.